Chiesi Farmaceutici S.p.a.

Vectura Gmbh

Chiara Malvolti

Raffaella Garzia

Gaetano Brambilla

Eva Bernini

Paolo Chiesi

David Andrew Lewis

Brian John Meakin

David Ganderton

Paolo Ventura

Rossella Musa

Rajbir Gill

Lorenzo Ferrarini

John Nicholas Staniforth

David Alexander Vodden Morton

Alessandra Ferraris

Michele Miozzi

Tanya Kathleen Church

Brian Meakin

Rosa Mezzadri

Davis Ganderton

Paolo Colombo

David Morton

Daniela Acerbi

Francesca Buttini

Timothy J Rouse

Robert Johnson

Rebecca Jaine Davies

Lorenzno Ferrarini

David Alexander Morton

David Howlett

The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Pharmaceutical solution formulations for pressurized metered dose inhalers

Crystalline microparticles consisting of a phenylalkylamino beta-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.

Crystalline microparticles of a beta-agonist coated with a fatty acid

Actuators for an aerosol inhalation device containing a housing adapted to receive an aerosol canister containing a pressurized medicament formulation, a mouthpiece portion through which the user inhales, a nozzle block and an orifice and a tubular element extending in the mouthpiece portion from the orifice aperture in a longitudinal axis substantially aligned with a longitudinal axis of the mouthpiece portion provide a significant reduction in the non-respirable, coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient. In addition the presence of the tubular element has minimal, negligible impact on the fine particle dose and on the particle size distribution (PSD) of the delivered particles having aerodynamic diameter lower than 9 &#x3bc;m.

Aerosol inhalation device

Pharmaceutical solution formulations for pressurised metered dose inhalers

A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.

Pharmaceutical formulations for dry powder inhalers

Microparticles comprising a combination of an anticholinergic, a beta-adrenoceptor agonist, and an inhaled corticosteroid are useful for the prevention and/or treatment of respiratory diseases.

Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic

Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.

Pharmaceutical aerosol composition

Pharmaceutical formulations comprising beclometasone dipropionate and a salt of formoterol exhibit improved stability and are useful in pressurized metered dose inhalers (pMDIs).

Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate

A metal container and a method of preparing a metal container for a pharmaceutical formulation where the active ingredient is formoterol, a stereoisomer of formoterol, and a physiologically acceptable salt of formoterol, in a solution of a liquefied HFA propellant.

Formoterol superfine formulation

A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 &#x3bc;m and a mass median diameter of at least 175 &#x3bc;m; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents.

Formulations for use in inhaler devices

The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is stainless steel, anodized aluminum, or lined with an inert organic coating and which contain a formulation which comprises ipratropium bromide.

Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining

The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting &#x3b2;-agonist by inhalation. In particular this invention relates to a chemically stable, highly efficient salmeterol HFA solution formulation to be administered by pressurized metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

Salmeterol superfine formulation

The invention relates to the use of pressurised metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating; and to compositions to be delivered with said MDIs.

Pressurised metered dose inhalers (MDI)

A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler, filling of an aerosol container and use of the composition for the administration of active materials by inhalation.

Growing community of inventors

Parma, Italy

Gaetano Brambilla